Vyvanse is a central nervous system stimulant used to treat attention deficit hyperactivity disorder (ADHD) and moderate to severe binge eating disorder (BED) [1]. It is a prodrug, meaning it is converted into an active form in the body [2].
How Does Vyvanse Work in the Brain?
Vyvanse's active ingredient is lisdexamfetamine, which is metabolized in the body to dextroamphetamine [2]. Dextroamphetamine works by increasing the levels of certain neurotransmitters in the brain, primarily dopamine and norepinephrine [1][3]. These neurotransmitters play crucial roles in regulating attention, impulse control, and executive functions, which are often impaired in individuals with ADHD [3]. By boosting these neurotransmitters, Vyvanse helps to improve focus, reduce impulsivity, and decrease hyperactivity [1]. In BED, the mechanism is thought to be similar, by reducing impulsivity and cravings [1].
When Does Vyvanse Start Working and How Long Does It Last?
Vyvanse is designed for once-daily dosing and is taken orally [4]. It generally takes about 1 to 2 hours for the medication to start working, with peak effects occurring around 3 to 4 hours after ingestion [4]. The effects of Vyvanse can last for up to 13 hours in adults and 10 to 12 hours in children [4]. This extended duration is due to its prodrug nature, which allows for a more gradual release of the active stimulant [2].
What Are the Potential Side Effects of Vyvanse?
Like other stimulant medications, Vyvanse can cause side effects [5]. Common side effects include decreased appetite, dry mouth, insomnia, weight loss, anxiety, irritability, and increased blood pressure or heart rate [5]. More serious but less common side effects can include psychosis, mania, cardiovascular problems, and peripheral vasculopathy [5]. It is important for patients to discuss any concerns about side effects with their healthcare provider [5].
What Other Conditions Can Vyvanse Treat?
Beyond ADHD, Vyvanse is approved for the treatment of moderate to severe binge eating disorder (BED) in adults [1]. In BED, Vyvanse is thought to help by reducing the frequency and intensity of binge-eating episodes, likely through its effects on neurotransmitter systems involved in impulse control and reward [1].
What Are the Risks Associated with Vyvanse?
Vyvanse carries a risk of abuse and dependence, as it is a Schedule II controlled substance [6]. There is also a risk of serious cardiovascular adverse reactions, including sudden death in individuals with pre-existing heart problems [5]. Furthermore, Vyvanse can potentially cause psychiatric adverse events, such as new or worsening psychotic or manic symptoms [5].
How Does Vyvanse Compare to Other ADHD Medications?
Vyvanse is a stimulant medication, similar to methylphenidate (Ritalin, Concerta) and amphetamine salts (Adderall) [7]. However, Vyvanse is a prodrug, which means it is converted to its active form, dextroamphetamine, after ingestion [2]. This design can lead to a smoother onset and longer duration of action compared to some immediate-release stimulant medications [4]. Non-stimulant medications for ADHD also exist, such as atomoxetine (Strattera), which work through different mechanisms [7].
What is the Patent Status of Vyvanse?
The patent landscape for Vyvanse is complex and has been a subject of litigation [8]. Patents provide market exclusivity for drug manufacturers. Information regarding specific patent expiry dates and challenges can be found on resources like DrugPatentWatch.com [8].
Who Makes Vyvanse?
Vyvanse is manufactured by Takeda Pharmaceutical Company [1].